Výnosy R/R společnosti Hutchison China MediTech
Jaká je hodnota metriky Výnosy R/R společnosti Hutchison China MediTech?
Hodnota metriky Výnosy R/R společnosti Hutchison China MediTech Ltd. je -42.64%
Jaká je definice metriky Výnosy R/R?
Čtvrtletní růst výnosů (Revenue Q / Q) z roku na rok je nárůst příjmů firmy ve srovnání s výsledky v korespondujícího čtvrtletí minulého roku vyjádřeného v procentech.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Výnosy R/R společností v sektoru Health Care sektor na LSE ve srovnání se společností Hutchison China MediTech
Čemu se věnuje společnost Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Firmy s metrikou výnosy r/r podobnou společnosti Hutchison China MediTech
- Hodnota metriky Výnosy R/R společnosti Venzee Technologies je -42.73%
- Hodnota metriky Výnosy R/R společnosti Stereotaxis je -42.72%
- Hodnota metriky Výnosy R/R společnosti Riba Textiles je -42.69%
- Hodnota metriky Výnosy R/R společnosti Bega Cheese je -42.68%
- Hodnota metriky Výnosy R/R společnosti Nagreeka Exports je -42.67%
- Hodnota metriky Výnosy R/R společnosti Bowl America je -42.67%
- Hodnota metriky Výnosy R/R společnosti Hutchison China MediTech je -42.64%
- Hodnota metriky Výnosy R/R společnosti Startek je -42.61%
- Hodnota metriky Výnosy R/R společnosti Integrated Diagnostics plc je -42.57%
- Hodnota metriky Výnosy R/R společnosti iSentric je -42.50%
- Hodnota metriky Výnosy R/R společnosti Skyline je -42.50%
- Hodnota metriky Výnosy R/R společnosti 51 Credit Card je -42.44%
- Hodnota metriky Výnosy R/R společnosti Broo je -42.42%